Profile
Ervin Veszprémi formerly worked at Medichem SA, as Chief Executive Officer from 2003 to 2014, Invent Invest Holding SL, as Chief Executive Officer from 2015 to 2016, Genmedica Therapeutics SL, as Chairman, Kindred Biosciences, Inc., as Independent Director from 2013 to 2021, Amersham Corp., as Head-Business Unit, Novartis Groupe France SA, as Vice President, Novartis Animal Health US, Inc., as Vice President & Global Head-Marketing in 2002, and Pharmacia Spain SA, as Head-Business Unit.
Mr. Veszprémi received his undergraduate degree from the University of British Columbia.
Former positions of Ervin Veszprémi
| Companies | Position | End |
|---|---|---|
| KINDRED BIOSCIENCES, INC. | Director/Board Member | 2021-08-26 |
Invent Invest Holding SL
Invent Invest Holding SL Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceuticals | Chief Executive Officer | 2016-10-03 |
Medichem SA
Medichem SA Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceutical ingredients | Chief Executive Officer | 2013-12-31 |
Novartis Groupe France SAS
Novartis Groupe France SAS Financial ConglomeratesFinance Functions as an investment holding company | Corporate Officer/Principal | - |
Novartis Animal Health US, Inc.
Novartis Animal Health US, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products for animals | Sales & Marketing | 2001-12-31 |
Training of Ervin Veszprémi
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 9 |
|---|---|
Amersham Corp.
Amersham Corp. Investment ManagersFinance Amersham Corp. focuses on the acquisition and ownership of mid-sized manufactures of precision engineered components and assemblies with particular interest in aerospace, automotive and medical device manufacturers and suppliers. The firm invests in small to medium sized companies with annual sales of $10 million to $200 million | Finance |
Kindred Biosciences, Inc.
Kindred Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for animals | Health Technology |
University of British Columbia
University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Groupe France SAS
Novartis Groupe France SAS Financial ConglomeratesFinance Functions as an investment holding company | Finance |
Genmedica Therapeutics SL
Genmedica Therapeutics SL BiotechnologyHealth Technology Engages in the research and development of treatments for metabolic disorders | Health Technology |
Novartis Animal Health US, Inc.
Novartis Animal Health US, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products for animals | Health Technology |
Medichem SA
Medichem SA Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceutical ingredients | Health Technology |
Pharmacia Spain SA | |
Invent Invest Holding SL
Invent Invest Holding SL Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceuticals | Health Technology |
- Stock Market
- Insiders
- Ervin Veszprémi
















